| Popis: |
Purpose. Study of the effect of 0.007% PABA solution in the form of the drug Aktipol-M on the inflammatory process based on the assessment of the level of sIL-6R and NE in the lacrimal fluid (LF), with dry eye disease (DED) in patients with diabetes mellitus (DM). Material and methods. The study involved 30 patients (60 eyes) with type 1 and 2 diabetes, aged 35 to 70 years, with a diagnosis of DED. Patients received Aktipol-M eye drops for one month. The contents of NE (10 patients, 20 eyes) and sIL-6R (20 patients, 40 eyes) were determined in the LF. The control group consisted of 10 healthy volunteers (20 eyes). Quantitative determination of the content of sIL-6R and NE was carried out by the method of enzyme-linked immunosorbent assay. Thirty patients (60 eyes) with type 1 and 2 diabetes, aged 35 to 70 years, with a diagnosis of DED were examined. The patients received Aktipol-M eye drops for one month. The content of NE (10 patients, 20 eyes) and sIL-6R (20 patients, 40 eyes) was determined in the LF. The control group consisted of 10 healthy volunteers (20 eyes). The quantitative determination of the content of sIL-6R and NE was carried out by the method of enzyme-linked immunosorbent assay. Results. The patients showed a higher content of sIL-6R (10974.8±1228.5 pkg/ml) and NE (3.85 ± 0.13 ng / ml) compared with the control group (4.6 ± 0.7 pkg / ml and 0.22 ± 0.08 ng/ml, respectively). After 1 month after the start of treatment, a significant decrease in these parameters was observed in all patients and in both eyes: on average, the content of sIL-6R by 80.5% and the NE content by 58.7%. Conclusion. PABA 0.007% in the dosage form of eye drops Aktipol-M has an anti-inflammatory effect, suppressing the production of sIL-6R and NE in the LF in DED in patients with diabetes. Key words: para-aminobenzoic acid, dry eye disease, diabetes mellitus, inflammation, neutrophilic elastase, soluble interleukin-6 receptor. |
